文献速递肾移植遗传性与小管间质肾病

欧洲高草酸尿症联盟登记研究中1型原发性高草酸尿症患者的长期移植结局

Long-Term Transplantation Outcomes in Patients With Primary Hyperoxaluria Type 1 Included in the European Hyperoxaluria Consortium (OxalEurope) Registry.
PubMed 文献 · Kidney Int Rep · 2021-11-26

该回顾性研究基于OxalEurope登记数据,分析1978至2019年间267例1型原发性高草酸尿症(PH1)患者的移植结局,其中244例(159例联合肝肾移植、48例孤立肾移植、37例序贯肝-肾移植)纳入比较分析。在维生素B6无反应基因型患者中,联合肝肾移植的无事件生存率和删失死亡后的肾移植物生存率更高;在B6反应型患者中,孤立肾移植的调整后死亡率更低(调整风险比0.07,95%CI 0.01-0.75,P=0.028)。

要点

  • B6无反应型PH1患者中,联合肝肾移植的调整后无事件生存率和删失死亡肾移植物生存率更高(P=0.025,P<0.001)。
  • B6反应型PH1患者中,孤立肾移植的调整后死亡率低于联合肝肾移植(调整风险比0.07,95%CI 0.01-0.75,P=0.028)。
  • 159例联合移植与37例序贯肝-肾移植的结局相当。

核心结论

  • 对于B6无反应基因型的PH1患者,联合肝肾移植或序贯肝-肾移植仍是首选的移植方式;对于B6反应基因型患者,孤立肾移植可能是一种替代方法。

研究设计与样本

  • 基于OxalEurope登记数据的回顾性分析,纳入1978年至2019年间接受移植的267例PH1患者,其中244例(159例联合肝肾移植、48例孤立肾移植、37例序贯肝-肾移植)纳入比较分析。
  • 采用Kaplan-Meier生存曲线和Cox比例风险模型进行粗生存分析和调整相对风险分析。

主要发现

  • 比较联合肝肾移植与孤立肾移植,B6无反应基因型患者的调整后死亡率相似,而B6反应基因型患者接受孤立肾移植的调整后死亡率更低(调整风险比0.07,95%CI 0.01-0.75,P=0.028)。
  • B6无反应基因型患者中,联合肝肾移植的调整后无事件生存率和删失死亡后的肾移植物生存率更高(P=0.025,P<0.001);B6反应基因型患者中则无显著差异(P=0.145,P=0.421)。
  • 159例联合移植与37例序贯肝-肾移植的结局相当。
  • 12例接受抢先肝移植的患者结局不佳。

临床怎么用

  • 原文结论指出,对于B6无反应基因型的PH1患者,联合肝肾移植或序贯肝-肾移植仍是首选的移植方式;对于B6反应基因型患者,孤立肾移植可能是一种替代方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In primary hyperoxaluria type 1 (PH1), oxalate overproduction frequently causes kidney stones, nephrocalcinosis, and kidney failure. As PH1 is caused by a congenital liver enzyme defect, combined liver-kidney transplantation (CLKT) has been recommended in patients with kidney failure. Nevertheless, systematic analyses on long-term transplantation outcomes are scarce. The merits of a sequential over combined procedure regarding kidney graft survival remain unclear as is the place of isolated kidney transplantation (KT) for patients with vitamin B6-responsive genotypes. METHODS: We used the OxalEurope registry for retrospective analyses of patients with PH1 who underwent transplantation. Analyses of crude Kaplan-Meier survival curves and adjusted relative hazards from the Cox proportional hazards model were performed. RESULTS: A total of 267 patients with PH1 underwent transplantation between 1978 and 2019. Data of 244 patients (159 CLKTs, 48 isolated KTs, 37 sequential liver-KTs [SLKTs]) were eligible for comparative analyses. Comparing CLKTs with isolated KTs, adjusted mortality was similar in patients with B6-unresponsive genotypes but lower after isolated KT in patients with B6-responsive genotypes (adjusted hazard ratio 0.07, 95% CI: 0.01-0.75, P = 0.028). CLKT yielded higher adjusted event-free survival and death-censored kidney graft survival in patients with B6-unresponsive genotypes (P = 0.025, P < 0.001) but not in patients with B6-responsive genotypes (P = 0.145, P = 0.421). Outcomes for 159 combined procedures versus 37 sequential procedures were comparable. There were 12 patients who underwent pre-emptive liver transplantation (PLT) with poor outcomes. CONCLUSION: The CLKT or SLKT remains the preferred transplantation modality in patients with PH1 with B6-unresponsive genotypes, but isolated KT could be an alternative approach in patients with B6-responsive genotypes.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Metry EL, Garrelfs SF, Peters-Sengers H, et al. Long-Term Transplantation Outcomes in Patients With Primary Hyperoxaluria Type 1 Included in the European Hyperoxaluria Consortium (OxalEurope) Registry. Kidney Int Rep. 2021. PMID: 35155860. doi:10.1016/j.ekir.2021.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。